Clinical Trial Update: Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

Phase 3 clinical study comparing macitentan and tadalafil monotherapies with a fixed-dose combination in pulmonary arterial hypertension. Results were posted on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Adcirca (tadalafil)
• OPSUMIT (macitentan)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Phase 3 | Status: COMPLETED | Results posted: 2023-11-13